Medicarpin suppresses lung cancer cell growth in vitro and in vivo by inducing cell apoptosis
References
- H. Sung, J. Ferlay, R. L. Siegel, M. Laversanne, I. Soerjomataram, A. Jemal and F. Bray, Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J. Clin. 71(3) (2021) 209–249; https://doi.org/10.3322/caac.21660
- W. D. Travis, E. Brambilla and G. J. Riely, New pathologic classification of lung cancer: relevance for clinical practice and clinical trials, J. Clin. Oncol. 31(8) (2013) 992–1001; https://doi.org/10.1200/jco.2012.46.9270
- A. T. Fathi and J. R. Brahmer, Chemotherapy for advanced stage non-small cell lung cancer, Semin. Thorac. Cardiovasc. Surg. 20(3) (2008) 210–216; https://doi.org/10.1053/j.semtcvs.2008.09.002
- A. Díaz-Serrano, P. Gella, E. Jiménez, J. Zugazagoitia and L. Paz-Ares Rodríguez, Targeting EGFR in lung cancer: Current standards and developments, Drugs 78(9) (2018) 893–911; https://doi.org/10.1007/s40265-018-0916-4
- M. Maemondo, A. Inoue, K. Kobayashi, S. Sugawara, S. Oizumi, H. Isobe, A. Gemma, M. Harada, H. Yoshizawa, I. Kinoshita, Y. Fujita, S. Okinaga, H. Hirano, K. Yoshimori, T. Harada, T. Ogura, M. Ando, H. Miyazawa, T. Tanaka, Y. Saijo, K. Hagiwara, S. Morita and T. Nukiwa, Gefitinib or chemo-therapy for non-small-cell lung cancer with mutated EGFR, N. Engl. J. Med. 362(25) (2010) 2380–2388; https://doi.org/10.1056/NEJMoa0909530
- M. Reck, D. Rodríguez-Abreu, A. G. Robinson, R. Hui, T. Csőszi, A. Fülöp, M. Gottfried, N. Peled, A. Tafreshi, S. Cuffe, M. O’Brien, S. Rao, K. Hotta, M. A. Leiby, G. M. Lubiniecki, Y. Shentu, R. Rang-wala and J. R. Brahmer, Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer, N. Engl. J. Med. 375(19) (2016) 1823–1833; https://doi.org/10.1056/NEJMoa1606774
- J. Xie, J. Liu, H. Liu, S. Liang, M. Lin, Y. Gu, T. Liu, D. Wang, H. Ge and S. L. Mo, The antitumor effect of tanshinone IIA on anti-proliferation and decreasing VEGF/VEGFR2 expression on the human non-small cell lung cancer A549 cell line, Acta Pharm. Sin. B. 5(6) (2015) 554–563; https://doi.org/10.1016/j.apsb.2015.07.008
- H. Luo, C. T. Vong, H. Chen, Y. Gao, P. Lyu, L. Qiu, M. Zhao, Q. Liu, Z. Cheng, J. Zou, P. Yao, C. Gao, J. Wei, C. O. L. Ung, S. Wang, Z. Zhong and Y. Wang, Naturally occurring anti-cancer compounds: shining from Chinese herbal medicine, Chin. Med. 14 (2019) Article ID 48 (58 pages); https://doi.org/10.1186/s13020-019-0270-9
- M. Kluska and K. Woźniak, Natural polyphenols as modulators of etoposide anti-cancer activity, Int. J. Mol. Sci. 22(12) (2021) Article ID 6602 (16 pages); https://doi.org/10.3390/ijms22126602
- J. Liang, N. Bi, S. Wu, M. Chen, C. Lv, L. Zhao, A. Shi, W. Jiang, Y. Xu, Z. Zhou, W. Wang, D. Chen, Z. Hui, J. Lv, H. Zhang, Q. Feng, Z. Xiao, X. Wang, L. Liu, T. Zhang, L. Du, W. Chen, Y. Shyr, W. Yin, J. Li, J. He and L. Wang, Etoposide and cisplatin versus paclitaxel and carboplatin with concurrent thoracic radiotherapy in unresectable stage III non-small cell lung cancer: a multicenter randomized phase III trial, Ann. Oncol. 28(4) (2017) 777–783; https://doi.org/10.1093/annonc/mdx009
- Y. Yoneshima, S. Morita, M. Ando, A. Nakamura, S. Iwasawa, H. Yoshioka, Y. Goto, M. Takeshita, T. Harada, K. Hirano, T. Oguri, M. Kondo, S. Miura, Y. Hosomi, T. Kato, T. Kubo, J. Kishimoto, N. Yamamoto, Y. Nakanishi and I. Okamoto, Phase 3 trial comparing nanoparticle albumin-bound paclitaxel with docetaxel for previously treated advanced NSCLC, J. Thorac. Oncol. 16(9) (2021) 1523–1532; https://doi.org/10.1016/j.jtho.2021.03.027
- X. Jiang, W. Zhao, F. Zhu, H. Wu, X. Ding, J. Bai, X. Zhang and M. Qian, Ligustilide inhibits the proliferation of non-small cell lung cancer via glycolytic metabolism, Toxicol. Appl. Pharmacol. 410 (2021) Article ID 115336 (25 pages); https://doi.org/10.1016/j.taap.2020.115336
- J. Zou, Y. Yang, Y. Yang and X. Liu, Polydatin suppresses proliferation and metastasis of non-small cell lung cancer cells by inhibiting NLRP3 inflammasome activation via NF-κB pathway, Biomed. Pharmacother. 108 (2018) 130–136; https://doi.org/10.1016/j.biopha.2018.09.051
- A. Ashaq, M. F. Maqbool, A. Maryam, M. Khan, H. A. Shakir, M. Irfan, J. I. Qazi, Y. Li and T. Ma, Hispidulin: A novel natural compound with therapeutic potential against human cancers, Phytother. Res. 35(2) (2021) 771–789; https://doi.org/10.1002/ptr.6862
- K. S. Prabhu, A. A. Bhat, K. S. Siveen, S. Kuttikrishnan, S. S. Raza, T. Raheed, A. Jochebeth, A. Q. Khan, M. Z. Chawdhery, M. Haris, M. Kulinski, S. Dermime, M. Steinhoff and S. Uddin, Sanguinarine mediated apoptosis in non-small cell lung cancer via generation of reactive oxygen species and suppression of JAK/STAT pathway, Biomed. Pharmacother. 144 (2021) Article ID 112358 (11 pages); https://doi.org/10.1016/j.biopha.2021.112358
- Y. Chen, L. Yin, M. Hao, W. Xu, J. Gao, Y. Sun, Q. Wang, S. Chen, Y. Liang, R. Guo, J. Zhang, J. Li, Q. Zhai, R. Cheng, J. Wang, H. Wang and Z. Yang, Medicarpin induces G1 arrest and mitochondria-mediated intrinsic apoptotic pathway in bladder cancer cells, Acta Pharm. 73(2) (2023) 211–225; https://doi.org/10.2478/acph-2023-0016
- J. H. Kim, D. M. Kang, Y. J. Cho, J. W. Hyun and M. J. Ahn, Medicarpin increases antioxidant genes by inducing NRF2 transcriptional level in HeLa cells, Antioxidants (Basel) 11(2) (2022) Article ID 421 (10 pages); https://doi.org/10.3390/antiox11020421
- B. Bhargavan, D. Singh, A. K. Gautam, J. S. Mishra, A. Kumar, A. Goel, M. Dixit, R. Pandey, L. Manic-kavasagam, S. D. Dwivedi, B. Chakravarti, G. K. Jain, R. Ramachandran, R. Maurya, A. Trivedi, N. Chattopadhyay and S. Sanyal, Medicarpin, a legume phytoalexin, stimulates osteoblast differentiation and promotes peak bone mass achievement in rats: evidence for estrogen receptor β-mediated osteogenic action of medicarpin, J. Nutr. Biochem. 23(1) (2012) 27–38; https://doi.org/10.1016/j.jnutbio.2010.11.002
- A. M. Tyagi, A. K. Gautam, A. Kumar, K. Srivastava, B. Bhargavan, R. Trivedi, S. Saravanan, D. K. Yadav, N. Singh, C. Pollet, M. Brazier, R. Mentaverri, R. Maurya, N. Chattopadhyay, A. Goel and D. Singh, Medicarpin inhibits osteoclastogenesis and has nonestrogenic bone conserving effect in ovariectomized mice, Mol. Cell. Endocrinol. 325(1–2) (2010) 101–109; https://doi.org/10.1016/j.mce.2010.05.016
- G. Gatouillat, A. A. Magid, E. Bertin, H. El btaouri, H. Morjani, C. Lavaud and C. Madoulet, Medicarpin and millepurpan, two flavonoids isolated from Medicago sativa, induce apoptosis and overcome multidrug resistance in leukemia P388 cells, Phytomedicine 22(13) (2015) 1186–1194; https://doi.org/10.1016/j.phymed.2015.09.005
- R. Trivedi, R. Maurya and D. P. Mishra, Medicarpin, a legume phytoalexin sensitizes myeloid leukemia cells to TRAIL-induced apoptosis through the induction of DR5 and activation of the ROSJNK-CHOP pathway, Cell Death Dis. 5(10) (2014) e1465; https://doi.org/10.1038/cddis.2014.429
- A. K. Yiğin, H. Donmez, M. Hitit, S. Seven, N. Eser, E. Kurar and M. Seven, The effect of medicarpin on PTEN/AKT signal pathway in head and neck squamous cell carcinoma, J. Cancer Res. Ther. 18(1) (2022) 180–184; https://doi.org/10.4103/jcrt.jcrt_641_21
- A. Mohr, L. Deedigan, S. Jencz, Y. Mehrabadi, L. Houlden, S. M. Albarenque and R. M. Zwacka, Caspase-10: a molecular switch from cell-autonomous apoptosis to communal cell death in response to chemotherapeutic drug treatment, Cell Death Differ. 25(2) (2018) 340–352; https://doi.org/10.1038/cdd.2017.164
- H. S. Chin, M. X. Li, I. K. L. Tan, R. L. Ninnis, B. Reljic, K. Scicluna, L. F. Dagley, J. J. Sandow, G. L. Kelly, A. L. Samson, S. Chappaz, S. L. Khaw, C. Chang, A. Morokoff, K. Brinkmann, A. Webb, C. Hockings, C. M. Hall, A. J. Kueh, M. T. Ryan, R. M. Kluck, P. Bouillet, M. J. Herold, D. H. D. Gray, D. C. S. Huang, M. F. van Delft and G. Dewson, VDAC2 enables BAX to mediate apoptosis and limit tumor development, Nat. Commun. 9(1) (2018) Article ID 4976 (13 pages); https://doi.org/10.1038/s41467-018-07309-4
- H. Xian and Y. C. Liou, Loss of MIEF1/MiD51 confers susceptibility to BAX-mediated cell death and PINK1-PRKN-dependent mitophagy, Autophagy 15(12) (2019) 2107–2125; https://doi.org/10.1080/15548627.2019.1596494
- L. Bai, H. M. Ni, X. Chen, D. DiFrancesca and X. M. Yin, Deletion of Bid impedes cell proliferation and hepatic carcinogenesis, Am. J. Pathol. 166(5) (2005) 1523–1532; https://doi.org/10.1016/s0002-9440(10)62368-1
- A. Wree, C. D. Johnson, J. Font-Burgada, A. Eguchi, D. Povero, M. Karin and A. E. Feldstein, Hepatocyte-specific Bid depletion reduces tumor development by suppressing inflammation-related compensatory proliferation, Cell Death Differ. 22(12) (2015) 1985–1994; https://doi.org/10.1038/cdd.2015.46
- M. J. Morgan and Z. G. Liu, Crosstalk of reactive oxygen species and NF-κB signaling, Cell Res. 21(1) (2011) 103–115; https://doi.org/10.1038/cr.2010.178
- C. Yu, S. Yan, B. Khambu, X. Chen, Z. Dong, J. Luo, G. K. Michalopoulos, S. Wu and X. M. Yin, Gene expression analysis indicates divergent mechanisms in DEN-induced carcinogenesis in wild type and Bid-deficient livers, PLoS One 11(5) (2016) e0155211; https://doi.org/10.1371/journal.pone.0155211
- S. H. Moon, C. H. Huang, S. L. Houlihan, K. Regunath, W. A. Freed-Pastor, J. P. t. Morris, D. F. Tschaharganeh, E. R. Kastenhuber, A. M. Barsotti, R. Culp-Hill, W. Xue, Y. J. Ho, T. Baslan, X. Li, A. Mayle, E. de Stanchina, L. Zender, D. R. Tong, A. D’Alessandro, S. W. Lowe and C. Prives, p53 represses the mevalonate pathway to mediate tumor suppression, Cell 176(3) (2019) 564–580; https://doi.org/10.1016/j.cell.2018.11.011
- D. Reddy, R. Kumavath, P. Ghosh and D. Barh, Lanatoside C induces G2/M cell cycle arrest and suppresses cancer cell growth by attenuating MAPK, Wnt, JAK-STAT, and PI3K/AKT/mTOR signaling pathways, Biomolecules 9(12) (2019) Article ID 792 (20 pages); https://doi.org/10.3390/biom9120792
- W. Hao, S. Wang and Z. Zhou, Tubeimoside-1 (TBMS1) inhibits lung cancer cell growth and induces cells apoptosis through activation of MAPK-JNK pathway, Int. J. Clin. Exp. Pathol. 8(10) (2015) 12075–12083.
- X. B. Jia, Q. Zhang, L. Xu, W. J. Yao and L. Wei, Lotus leaf flavonoids induce apoptosis of human lung cancer A549 cells through the ROS/p38 MAPK pathway, Biol. Res. 54(1) (2021) Article ID 7 (15 pages); https://doi.org/10.1186/s40659-021-00330-w
- T. Otto and P. Sicinski, Cell cycle proteins as promising targets in cancer therapy, Nat. Rev. Cancer 17(2) (2017) 93–115; https://doi.org/10.1038/nrc.2016.138
- Y. Hu, K. Yu, G. Wang, D. Zhang, C. Shi, Y. Ding, D. Hong, D. Zhang, H. He, L. Sun, J. N. Zheng, S. Sun and F. Qian, Lanatoside C inhibits cell proliferation and induces apoptosis through attenuating Wnt/β-catenin/c-Myc signaling pathway in human gastric cancer cell, Biochem. Pharmacol. 150 (2018) 280–292; https://doi.org/10.1016/j.bcp.2018.02.023
- M. Rasheduzzaman, H. Yin and S. Y. Park, Cardiac glycoside sensitized hepatocellular carcinoma cells to TRAIL via ROS generation, p38MAPK, mitochondrial transition, and autophagy mediation, Mol. Carcinog. 58(11) (2019) 2040–2051; https://doi.org/10.1002/mc.23096
- I. Durmaz, E. B. Guven, T. Ersahin, M. Ozturk, I. Calis and R. Cetin-Atalay, Liver cancer cells are sensitive to lanatoside C induced cell death independent of their PTEN status, Phytomedicine 23(1) (2016) 42–51; https://doi.org/10.1016/j.phymed.2015.11.012
- A. Rauf, T. Abu-Izneid, A. A. Khalil, M. Imran, Z. A. Shah, T. B. Emran, S. Mitra, Z. Khan, F. A. Alhu maydhi, A. S. M. Aljohani, I. Khan, M. M. Rahman, P. Jeandet and T. A. Gondal, Berberine as a potential anticancer agent: A comprehensive review, Molecules 26(23) (2021) Article ID 7368 (19 pages); https://doi.org/10.3390/molecules26237368+
- D. Bertheloot, E. Latz and B. S. Franklin, Necroptosis, pyroptosis and apoptosis: an intricate game of cell death, Cell. Mol. Immunol. 18(5) (2021) 1106–1121; https://doi.org/10.1038/s41423-020-00630-3
- D. E. Hong, J. E. Yu, J. W. Lee, D. J. Son, H. P. Lee, Y. Kim, J. Y. Chang, D. W. Lee, W. K. Lee, J. Yun, S. B. Han, B. Y. Hwang and J. T. Hong, A natural CHI3L1-targeting compound, ebractenoid f, inhibits lung cancer cell growth and migration and induces apoptosis by blocking CHI3L1/AKT signals, Molecules 28(1) (2022) Article ID 329 (16 pages); https://doi.org/10.3390/molecules28010329
Language: English
Page range: 149 - 164
Accepted on: Feb 13, 2024
Published on: Mar 30, 2024
Published by: Croatian Pharmaceutical Society
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
Related subjects:
© 2024 Zongyi Shen, Liqi Yin, Manxia Chang, Haifeng Wang, Mingxuan Hao, Youfeng Liang, Rui Guo, Ying Bi, Jiansong Wang, Changyuan Yu, Jinmei Li, Qiongli Zhai, Runfen Cheng, Jinku Zhang, Jirui Sun, Zhao Yang, published by Croatian Pharmaceutical Society
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.